Verona Pharma Plc

NASDAQ: VRNA
$38.58
+$0.40 (+1.0%)
Closing Price on November 8, 2024

VRNA Stock Chart and Intraday Price

VRNA Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 3 MORE LONDON RIVERSIDE, LONDON, GB
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 1,454.11M USD
Shares Outstanding 79,940,000
Verona Pharma Plc is a London-based biopharmaceutical company focused on creating treatments for respiratory diseases lacking adequate therapies. Its leading product, ensifentrine, is a novel compound with dual action as a bronchodilator and anti-inflammatory agent, currently in Phase 3 trials for conditions like chronic obstructive pulmonary disease, asthma, and cystic fibrosis. Verona Pharma is exploring ensifentrine in various forms, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, aiming to meet critical healthcare needs.

VRNA Articles

Tuesday's top analyst upgrades and downgrades included Apple, Azul, Conagra Brands, Corteva, CSX, Deere, DraftKings, Foot Locker, Intuit, KeyCorp, Nike, Salesforce, Take-Two Interactive Software,...
Tuesday's top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup,...
Monday's additional top analyst upgrades and downgrades were on Array Technologies, ConocoPhillips, EQT, KB Home, Lennar, NetApp, Netflix and more.
Monday’s top analyst upgrades and downgrades included Affirm, AstraZeneca, Broadcom, Centene, Dell Technologies, Dollar General, Marvell Technology, Medical Properties Trust, Tesla, Ulta Beauty,...
Friday's additional top analyst upgrades and downgrades were on Burlington Stores, Forge Global, Gap, Ulta Beauty, Zoom Video Communications and more.
Monday's top analyst upgrades and downgrades included Albermarle, Apple, Consolidated Edison, Etsy, GoHealth, Hecla Mining, NortonLifeLock, Pinterest, Switch and T-Mobile.